| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC5A5 |
| Uniprot No | Q92911 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-643aa |
| 氨基酸序列 | MEAVETGERPTFGAWDYGVFALMLLVSTGIGLWVGLARGGQRSAEDFFTGGRRLAALPVGLSLSASFMSAVQVLGVPSEAYRYGLKFLWMCLGQLLNSVLTALLFMPVFYRLGLTSTYEYLEMRFSRAVRLCGTLQYIVATMLYTGIVIYAPALILNQVTGLDIWASLLSTGIICTFYTAVGGMKAVVWTDVFQVVVMLSGFWVVLARGVMLVGGPRQVLTLAQNHSRINLMDFNPDPRSRYTFWTFVVGGTLVWLSMYGVNQAQVQRYVACRTEKQAKLALLINQVGLFLIVSSAACCGIVMFVFYTDCDPLLLGRISAPDQYMPLLVLDIFEDLPGVPGLFLACAYSGTLSTASTSINAMAAVTVEDLIKPRLRSLAPRKLVIISKGLSLIYGSACLTVAALSSLLGGGVLQGSFTVMGVISGPLLGAFILGMFLPACNTPGVLAGLGAGLALSLWVALGATLYPPSEQTMRVLPSSAARCVALSVNASGLLDPALLPANDSSRAPSSGMDASRPALADSFYAISYLYYGALGTLTTVLCGALISCLTGPTKRSTLAPGLLWWDLARQTASVAPKEEVAILDDNLVKGPEELPTGNKKPPGFLPTNEDRLFFLGQKELEGAGSWTPCVGHDGGRDQQETNL |
| 预测分子量 | 68.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC5A5(钠碘同向转运体)重组蛋白研究的3篇代表性文献的简要信息：
1. **文献名称**：*"Functional characterization of the human sodium/iodide symporter in a mammalian cell line"*
**作者**：Dohan O, et al.
**摘要**：研究通过重组技术将人源SLC5A5在HEK293细胞中表达，验证其碘转运功能及对甲状腺激素合成的重要性，为放射性碘治疗甲状腺疾病提供模型基础。
2. **文献名称**：*"Structural insights into the sodium/iodide symporter (NIS) by cryo-EM"*
**作者**：Portulano C, et al.
**摘要**：利用冷冻电镜解析重组SLC5A5蛋白的三维结构，揭示其底物结合域和钠离子协同转运机制，为靶向药物设计提供结构依据。
3. **文献名称**：*"Recombinant NIS-expressing cells as a platform for cancer gene therapy"*
**作者**：Spitzweg C, et al.
**摘要**：将重组SLC5A5导入非甲状腺癌细胞，增强其碘摄取能力，探索其在放射性碘治疗非甲状腺肿瘤(如乳腺癌、前列腺癌)中的潜在应用。
4. **文献名称**：*"Regulation of the sodium/iodide symporter by TSH and cAMP in recombinant thyroid cells"*
**作者**：Riedel C, et al.
**摘要**：在重组甲状腺细胞模型中研究TSH和cAMP信号对SLC5A5表达的调控，阐明其在甲状腺功能亢进或减退症中的分子机制。
(注：以上文献为领域内典型研究方向示例，具体标题和作者可能有调整，建议通过PubMed或Google Scholar核对最新研究。)
SLC5A5. also known as the sodium/iodide symporter (NIS), is a transmembrane glycoprotein encoded by the *SLC5A5* gene. It belongs to the solute carrier family 5 (SLC5) of transporters and plays a critical role in iodide uptake, primarily in thyroid follicular cells, where it facilitates the concentration of iodide required for thyroid hormone synthesis. NIS couples the translocation of sodium ions (Na⁺) down their electrochemical gradient with the uphill transport of iodide (I⁻) into cells, a process essential for thyroid function. Beyond the thyroid, NIS is expressed in other tissues, including salivary glands, gastric mucosa, and lactating mammary glands, though its physiological roles in these sites are less understood.
Recombinant SLC5A5 protein is engineered using heterologous expression systems, such as mammalian cell lines (e.g., HEK293) or bacteria, to study its structure-function relationships, regulatory mechanisms, and interactions with drugs or mutations. This protein has garnered significant interest in both basic research and clinical applications. For instance, recombinant NIS is pivotal in investigating thyroid disorders like congenital iodide transport defects or dysregulated iodide uptake in thyroid cancers. Additionally, it serves as a therapeutic target for radioiodine therapy in differentiated thyroid carcinomas, leveraging its ability to concentrate radioactive iodine (¹³¹I) selectively in cancer cells.
Recent advances in recombinant protein technology have enabled detailed characterization of NIS post-translational modifications, trafficking, and pharmacodynamics. Furthermore, NIS-based gene therapy approaches are being explored to restore iodide uptake in NIS-deficient cancers or to enable non-thyroidal cancers to absorb radioisotopes for targeted ablation. Challenges remain in optimizing recombinant NIS stability and activity in vitro, as well as minimizing off-target effects in therapeutic contexts. Overall, SLC5A5 recombinant protein remains a vital tool for unraveling iodide metabolism and developing precision therapies for thyroid and other malignancies.
×
